GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » Cyclically Adjusted PS Ratio

Curis (CRIS) Cyclically Adjusted PS Ratio : 2.34 (As of Apr. 30, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Curis Cyclically Adjusted PS Ratio?

As of today (2024-04-30), Curis's current share price is $15.35. Curis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $6.57. Curis's Cyclically Adjusted PS Ratio for today is 2.34.

The historical rank and industry rank for Curis's Cyclically Adjusted PS Ratio or its related term are showing as below:

CRIS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.58   Med: 6.32   Max: 24.32
Current: 2.24

During the past years, Curis's highest Cyclically Adjusted PS Ratio was 24.32. The lowest was 0.58. And the median was 6.32.

CRIS's Cyclically Adjusted PS Ratio is ranked better than
70.16% of 506 companies
in the Biotechnology industry
Industry Median: 5.395 vs CRIS: 2.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Curis's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.467. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.57 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Curis Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Curis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Cyclically Adjusted PS Ratio Chart

Curis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.52 14.10 9.25 1.30 1.94

Curis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.30 1.40 2.13 0.97 1.94

Competitive Comparison of Curis's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Curis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Cyclically Adjusted PS Ratio falls into.



Curis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Curis's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=15.35/6.57
=2.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Curis's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.467/129.4194*129.4194
=0.467

Current CPI (Dec. 2023) = 129.4194.

Curis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.496 99.695 1.942
201406 5.583 100.560 7.185
201409 2.052 100.428 2.644
201412 2.316 99.070 3.025
201503 1.537 99.621 1.997
201506 1.622 100.684 2.085
201509 1.593 100.392 2.054
201512 1.627 99.792 2.110
201603 1.338 100.470 1.724
201606 1.299 101.688 1.653
201609 1.332 101.861 1.692
201612 1.678 101.863 2.132
201703 1.501 102.862 1.889
201706 1.433 103.349 1.794
201709 1.668 104.136 2.073
201712 1.987 104.011 2.472
201803 1.493 105.290 1.835
201806 1.423 106.317 1.732
201809 1.717 106.507 2.086
201812 1.664 105.998 2.032
201903 1.066 107.251 1.286
201906 1.263 108.070 1.513
201909 1.720 108.329 2.055
201912 1.980 108.420 2.363
202003 1.572 108.902 1.868
202006 1.194 108.767 1.421
202009 1.005 109.815 1.184
202012 0.916 109.897 1.079
202103 0.478 111.754 0.554
202106 0.499 114.631 0.563
202109 0.664 115.734 0.743
202112 0.684 117.630 0.753
202203 0.449 121.301 0.479
202206 0.522 125.017 0.540
202209 0.602 125.227 0.622
202212 0.599 125.222 0.619
202303 0.475 127.348 0.483
202306 0.454 128.729 0.456
202309 0.495 129.860 0.493
202312 0.467 129.419 0.467

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Curis  (NAS:CRIS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Curis Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Curis's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Curis (CRIS) Business Description

Industry
Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Executives
Jonathan B. Zung officer: CDO C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Kenneth I Kaitin director C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111
Martyn D Greenacre director 41 MOORES ROAD, FRAZER PA 19355
Robert Martell officer: Head of Research & Development 4 MAGUIRE ROAD, LEXINGTON MA 02421
Diantha Duvall officer: CFO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James E Dentzer director, officer: President & CEO C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
William Steinkrauss officer: VP, Finance & Treasurer, other: Principal Accounting Officer C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Fattaey Ali Ph.d. officer: President & COO C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Aurigene Discovery Technologies Ltd 10 percent owner 39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100
David Tuck officer: Sr. Vice-President C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421